

IN THE DRAWINGS:

Please delete Drawing Sheet Nos. 2, 5, 9 and 14.

REMARKS

In the Office Action dated May 4, 2005, claims 1-89 are pending. Claims 2-9, 14-17, 21-49, 51-58, 63-66 and 70-89 are withdrawn from further consideration as drawn to non-elected subject matter. Claims 1, 10-13, 18-20, 50, 59-62 and 67-69 are under consideration and are rejected. The Examiner has also objected to the application for certain alleged informalities.

This Response addresses each of the Examiner's rejections and objections. Applicants therefore respectfully submit that the present application is in condition for allowance. Favorable consideration of all pending claims is therefore respectfully requested.

In the Office Action, the Examiner states that Applicants have not complied with the conditions for receiving the benefit of an earlier filing date. Specifically, the Examiner states that the application does not include a reference to prior Application No. 60/141,441, filed June 29, 1999. The specification and the application data sheet only referenced International Application PCT/AU00/00786, filed on June 29, 2000. The Examiner also indicates that as the specified time period to submit the priority reference has expired, a petition must be filed in accordance with 37 C.F.R. §1.78 to claim priority from Provisional Application 60/141,441.

In response, Applicants are providing herewith a Petition in accordance with 37 C.F.R. §1.78(a)(6) to claim priority from Provisional Application 60/141,44. The Petition is accompanied by the requisite official fee specified in 37 C.F.R. §1.17(t). The specification has also been amended to add a cross reference to the Provisional Application.

The Examiner also objects to the application for identifying the sequences by "<400>", rather than by "SEQ ID NO".

Applicants have amended the specification to address the objection. Withdrawal of the objection to the specification is therefore respectfully requested.

Furthermore, the Examiner objects to the drawings for failure to comply with 37 C.F.R. §1.84(u)(1) and for including pages only to illustrate the relationship of subparts of a figure.

Applicants have deleted Drawing Sheet Nos. 2, 5, 9 and 14, which were included only to illustrate the relationship of subparts of the relevant Figures. In addition, Applicants have amended the Brief Description of the Drawings to appropriately reference the drawing numbers. Withdrawal of the objection to the drawings is therefore respectfully requested.

Claims 1, 10-13, 18-20, 50, 59-62 and 67-69 are rejected under 35 U.S.C. §101, allegedly because the claimed invention is not supported by either a specific, substantial and credible asserted utility or a well established utility. These claims are also rejected under 35 U.S.C. §112, first paragraph. The Examiner contends that since the claimed invention is not supported by either a specific, substantial and credible asserted utility or a well established utility, one skilled in the art would not know how to use the claimed invention without undue experimentation.

The Examiner acknowledges that the specification discloses three specific nucleic acid molecules that are expressed at higher levels in liver tissue of obese or fed animals compared to lean or fasted animals. However, the Examiner contends that the specification does not provide for any biological activity of the encoded protein or any nexus between the claimed nucleic acid molecules and any disease or condition. The Examiner is of the opinion that until some actual and specific significance can be attributed to the claimed nucleic acid molecules, those skilled in the art would be required to perform additional experimentation in order to determine how to use the claimed invention. Thus, the Examiner concludes that there was no immediately apparent or "real world" utility as of the filing date.

Applicants respectfully disagree with the Examiner's assertion. Applicants have identified, *inter alia*, that the B55 molecule is specifically associated with insulin resistance and type 2 diabetes. More specifically, as disclosed in the specification (for example, pages 55-56), a polynucleotide encoding B55 was found to be increased markedly in both liver and adipose tissue in response to fasting. These data demonstrate that B55 acts in a protective manner in these tissues, and is required for the body to adequately cope with stresses such as food deprivation. There is also evidence that under non-stressful conditions ("fed" state), hepatic B55

expression was reduced in insulin resistant and type 2 diabetic animals, suggesting that a relative lack of B55 under these conditions was associated with impaired glucose metabolism.

Therefore, collectively these data demonstrate that increased expression of B55 would be beneficial for the treatment of insulin resistance and type 2 diabetes.

Thus, Applicants respectfully submit that the present application has asserted a specific and substantial utility of the claimed nucleic acid molecules. Those skilled in the art would fully recognize that B55 has therapeutic utility on the basis of its association with fasting and type 2 diabetes. Withdrawal of the rejection is respectfully requested.

Claims 1, 10-13, 18-20, 50, 59-62 and 67-69 are rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement. Specifically, the Examiner contends that the claims do not require that the nucleic acid encode a protein that possesses any particular biological activity, nor any particular conserved structure, nor other disclosed distinguishing feature. Thus, the claims are drawn to a genus of nucleic acids that are defined only by expression pattern or some degree of sequence identity.

For the purpose of expediting prosecution, Applicants have cancelled previous claims 1-89 and are presenting new Claims 90-95. Support for new claims 90-91 is found in previous claims 10 and 59. Support for new claims 92-93 is found in previous claims 11 and 60. Support for new claims 94-95 is found in previous claims 18 and 67. The reference to "at least 90% similarity" in claim 90 is supported by the specification, e.g., on page 17, line 27. The reference to hybridization conditions in claims 92 and 94 is supported by the specification, e.g., on page 18, lines 1-16. Support for the functional characterization "increased expression of said sequence is useful in the treatment of diabetes", is found in the specification, e.g., on page 34, lines 28-32; page 37, lines 24-27.

Applicants respectfully submit that the present specification has described, *inter alia*, the identification of B55 and its therapeutic applications in insulin resistance and type 2 diabetes. Therefore, contrary to the Examiner's contention, the specification has described a biological activity/function for the molecules as presently claims.

Furthermore, instant claims 90-95 not only include the recitation of specific sequences, i.e. SEQ ID NOs: 5, 6 and 9, but also include the functional characteristic that the "increased expression of said sequence is useful in the treatment of diabetes". As presently recited, the claimed nucleic acid molecules are characterized in both structural and functional language in full compliance with the written description requirement. Accordingly, the written description rejection under 35 U.S.C. §112, first paragraph, is overcome. Withdrawal of the rejection is respectfully requested.

Claims 1, 10-13, 18-20, 50, 59-62 and 67-69 are further rejected under 35 U.S.C. §112, second paragraph, as allegedly indefinite. Specifically, the Examiner objects to the recitations "substantially as set forth", "at least about" and "low stringency", as well as the language referring to derivative, homologue, mimetic and/or analogue.


Applicants respectfully submit that the new claims presented in the instant amendment obviate the rejection. Withdrawal of the rejection is therefore respectfully requested.

Claims 1, 10-13, 18-20, 50, 59-62 and 67-69 are rejected under 35 U.S.C. §102(e) as allegedly anticipated by Rosen et al. (US 2002/0055627). According to the Examiner, Rosen et al. disclose a nucleic acid that is 100% identical to instant SEQ ID NO: 5 (see SEQ ID NO: 140 of Rosen et al.). The Examiner concedes that Rosen et al. do not teach a nucleic acid molecule that is 100% identical with instant SEQ ID NO: 9. However, the Examiner contends that the molecule of Rosen et al. would be expected to hybridize under low stringency conditions, since there are substantial portions of SEQ ID NO: 9 that are identical with portions of the molecule of Rosen et al.

Applicants will address the rejection in a supplemental response.

In view of the foregoing amendments and remarks, it is firmly believed that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser
400 Garden City Plaza-Ste 300
Garden City, New York 11530
Telephone: 516-742-4343
XZ:ab

Encs.:

- Marked-up and clean copies of substitute specification;
- Petition under 37 CFR 1.78(a)(6).



SUBSTITUTE SPECIFICATION

(MARKED UP VERSION)



5 **NOVEL GENES AND THEIR USE IN THE
MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE**

CROSS REFERENCE TO RELATED APPLICATIONS

10

This application is a continuation of International Application No. PCT/AU00/00786, filed on June 29, 2000, which claims priority from Provisional Application No. 60/141,441, filed June 29, 1999.

15 **FIELD OF THE INVENTION**

The present invention relates generally to nucleic acid molecules encoding proteins associated with the modulation of obesity, diabetes and/or metabolic energy levels. More particularly, the present invention is directed to nucleic acid molecules and the
20 recombinant and purified proteins encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecules and proteins and their derivatives, homologs, analogs, chemical equivalents and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance.

25

BACKGROUND OF THE INVENTION

Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

30

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that prior art forms part of the common general knowledge in Australia.

35 Obesity is defined as the pathological condition of increased body fat content and is thought to result from the sustained imbalance between energy intake and energy

expenditure. The incidence of this metabolic disorder is high, affecting approximately 23% of adult Americans (Flegal *et al.* 1998).

The high incidence of obesity amounts to a serious public health problem due to the increased risk of complications such as cardiovascular disease, type 2 diabetes and certain types of cancer (Bouchard 1994). Type 2 diabetes may be defined as a pathological increase in blood glucose concentration. It characteristically develops in obese, middle-aged individuals and, if not adequately controlled, leads to the onset of complications such as blindness, renal failure and peripheral vascular insufficiency. As with obesity, type 2 diabetes is highly prevalent in both affluent and developing societies, with an estimated prevalence rate of 5-10% in adult Americans (Harris *et al.* 1998).

The prevalence rates of both obesity and type 2 diabetes continue to increase worldwide (Bennet and Magnus 1994; Bouchard 1994; Flegal *et al.* 1998; Harris *et al.* 1998). In addition, certain ethnic (e.g. Native American, Australian Aborigines, Pacific Islanders) and socioeconomic groups (low income) appear to be particularly susceptible to the onset of obesity and diabetes (Zimmet *et al.* 1995; Harris *et al.* 1998; Martikainen and Marmot 1999; Story *et al.* 1999). The public health impacts of obesity and type 2 diabetes onset are reflected by the high cost burden imposed by these diseases. It has been estimated that type 2 diabetes alone accounts for 2-3% of the total health care budget in every country worldwide (Jonsson 1998), costing about US\$40 billion annually in the USA alone (Bouchard 1994). In addition, the indirect costs of type 2 diabetes have been estimated using "disability-adjusted life-years" (DALYs). In 1990, 7.97 million DALYs were lost due to type 2 diabetes onset. Similarly, obesity imposes a substantial economic burden on society both directly and indirectly through the close relationship between obesity and its complications such as cardiovascular disease and type 2 diabetes.

Obesity and type 2 diabetes are both systemic diseases with ill-defined etiology and pathophysiology. However, several tissues have been implicated in the disease processes including the hypothalamus, liver and adipose tissue. The hypothalamus plays a central role in energy balance and factors produced by and/or acting on the hypothalamus have been extensively investigated. These factors include neuropeptide Y, corticotropin-releasing factor, melanin-concentrating hormone, leptin and many other proteins which affect food intake in experimental animal models. It has been proposed that genetic

alterations perturbing the metabolic pathways that regulate energy balance in the hypothalamus could contribute to the development of obesity, and subsequently diabetes.

5 The liver is thought to play a significant role in carbohydrate metabolism, as it is the only organ in which glucose is produced. It is also a major site of glucose storage in the form of glycogen. Alteration in the output of glucose from the liver ("elevated hepatic glucose output") is an early pathological event in the development of type 2 diabetes, and together with reduced clearance of glucose from the blood, is a significant contributor to the rise in blood glucose concentration which is characteristic of type 2 diabetes. In addition, the
10 liver is a large organ and alterations in the metabolic activity of the liver may contribute to overall variations in whole body energy expenditure.

Adipose tissue is the site of fat storage for the body, and is the principal organ involved in the development of obesity as it is the site of excess fat storage. Previously thought to be
15 rather metabolically inert, recent studies have shown that a number of factors are secreted from adipose tissue, which factors may act to regulate energy balance and other metabolic processes. For example, leptin is secreted by adipose tissue and is thought to act on the hypothalamus to reduce food intake and increase energy expenditure (Zhang *et al.* 1994). It is considered likely that other factors produced by adipocytes may act either locally or
20 systemically to regulate energy balance.

In work leading up to the present invention the inventors have identified novel genes which are differentially expressed in association with obesity, diabetes and energy metabolism. The identification of these genes permits the rational design of drugs for the
25 modulation of the functional activity of these genes and the further identification of a range of molecules for use in therapy, diagnosis, antibody generation and modulation of obesity, diabetes or energy metabolism.

SUMMARY OF THE INVENTION

30

The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210> 1,

<210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively.

Nucleotide and amino acid sequences referred to in the specification are defined by the
5 information provided in numeric indicator <400>SEQ ID NO: followed by the sequence identifier (eg. <400>SEQ ID NO:1, <400>SEQ ID NO:2, etc). A summary of the sequences with given SEQ ID NOS is provided before the Examples.

Throughout this specification and the claims which follow, unless the context requires
10 otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

One aspect of the present invention provides an isolated nucleic acid molecule or
15 derivative, homologue or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a protein or a derivative, homologue or mimetic of said protein wherein said nucleic acid molecule is differentially expressed in liver tissue of obese animals compared to lean animals.

20 Another aspect of the present invention provides an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a protein or a derivative, homologue or mimetic of said protein wherein said nucleic acid molecule is differentially expressed in liver tissue of fed animals compared to fasted animals.

25 Yet another aspect of the present invention provides an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:2 or a derivative, homologue or
30 mimetic thereof or having at least about 45% similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:2.

Still another aspect of the present invention contemplates an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence

substantially as set forth in <400>SEQ ID NO:1 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:1 under low stringency conditions.

5 Still yet another aspect of the present invention contemplates a nucleic acid molecule or a derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:1 or a derivative or homologue thereof or capable of hybridising to <400>SEQ ID NO:1 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>SEQ ID NO:2 or a sequence having at least about 45 % similarity to at least 10
10 contiguous amino acids in <400>SEQ ID NO:2.

Yet still another aspect of the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:1.

15 A further aspect of the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:4 or a derivative, homologue or mimetic thereof or having at least about 45 % similarity to at least 10 contiguous amino
20 acids in <400>SEQ ID NO:4.

Another further aspect of the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:3 or a derivative or homologue thereof, or capable of
25 hybridising to <400>SEQ ID NO:3 under low stringency conditions.

Still another further aspect of the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:3 or a derivative or homologue thereof or
30 capable of hybridising to <400>SEQ ID NO:3 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>SEQ ID NO:4 or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:4.

Yet another further aspect of the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:3.

5 Still yet another further aspect of the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:6 or a derivative, homologue or mimetic thereof or having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

10

Yet still another further aspect of the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:5 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:5 under low stringency conditions.

15

Another aspect of the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:5 or a derivative, homologue or mimetic thereof or capable of hybridising to <400>SEQ ID NO:5 under low stringency conditions and
20 which encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>SEQ ID NO:6 or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

25 Yet another aspect of the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:5.

Still yet another aspect of the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid
30 sequence substantially as set forth in <400>SEQ ID NO:8 or a derivative, homologue or mimetic thereof or having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:8.

Still another aspect of the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:7 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:7 under low stringency conditions.

5

A further aspect of the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:7 or a derivative, homologue or mimetic thereof or capable of hybridising to <400>SEQ ID NO:7 under low stringency conditions and
10 which encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>SEQ ID NO:8 or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:8.

Another further aspect of the present invention contemplates a nucleic acid molecule
15 comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:7.

In yet another further aspect, the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid
20 sequence substantially as set forth in <400>SEQ ID NO:6 or a derivative, homologue or mimetic thereof or having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

Still another further aspect of the present invention contemplates a nucleic acid molecule
25 or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:9 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:9 under low stringency conditions.

Yet another further aspect of the present invention contemplates a nucleic acid molecule or
30 derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:9 or a derivative, homologue or mimetic thereof or capable of hybridising to <400>SEQ ID NO:9 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth

in <400>SEQ ID NO:6 or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

5 Still yet another further aspect of the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:9.

10 Another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:1 or a derivative or homologue thereof under low stringency conditions at 42°C.

15 Yet another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:3 or a derivative or homologue thereof under low stringency conditions at 42°C.

Still another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:7 or a derivative or homologue thereof under low stringency conditions at 42°C.

20 Still yet another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:5 or a derivative or homologue thereof under low stringency conditions.

25 Yet another aspect of the present invention contemplates a cDNA nucleic acid molecule or derivative, homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:9 or a derivative or homologue thereof under low stringency conditions.

30 In another aspect the nucleotide sequence corresponding to *B38* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:1 or a derivative, homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:1.

In still another aspect the nucleotide sequence corresponding to *B55* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:3 or a derivative, homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:3.

5

In yet another aspect the nucleotide sequence corresponding to *B55* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:5 or a derivative homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:5.

10

In still yet another aspect the nucleotide sequence corresponding to *B55* is a genomic sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:9 or a derivative homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:9.

15

In yet a further aspect of the nucleotide sequence corresponding to *B60* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:7 or a derivative, homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:7.

20

A derivative of the nucleic acid molecule of the present invention also includes a nucleic acid molecule capable of hybridising to a nucleotide sequence as set forth in any one or more of <400>SEQ ID NO: 1, <400>SEQ ID NO:3, <400>SEQ ID NO:5, <400>SEQ ID NO:7 or <400>SEQ ID NO:9 under low stringency conditions.

25 Preferably, low stringency is at 42°C.

Another aspect of the present invention is directed to an isolated protein selected from the list consisting of:

- 30 (i) a protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in liver tissue of obese animals compared to lean animals or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.

- (ii) a protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in liver tissue of fed animals compared to fasted animals or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.
- 5 (iii) B38, B55 or B60 or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.
- (iv) a protein having an amino acid sequence substantially as set forth in <400>SEQ ID NO:2 or a derivative, homologue or mimetic thereof or a sequence having at
10 least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:2 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- (v) a protein having an amino acid sequence substantially as set forth in <400>SEQ ID NO:4 or a derivative, homologue or mimetic thereof or a sequence having at
15 least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:4 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- 20 (vi) a protein having an amino acid sequence substantially as set forth in <400>SEQ ID NO:6 or a derivative, homologue or mimetic thereof or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- 25 (vii) a protein having an amino acid sequence substantially as set forth in <400>SEQ ID NO:8 or a derivative, homologue or mimetic thereof or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:8 or a derivative, homologue, analogue, chemical equivalent or mimetic of
30 said protein.
- (viii) a protein encoded by a nucleotide sequence substantially as set forth in <400>SEQ ID NO:1 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45 % similarity to

at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:2 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

- 5 (ix) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:3 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:4 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- 10 (x) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:5 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- 15 (xi) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:7 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:8 or a derivative,
- 20 homologue, analogue, chemical equivalent or mimetic of said protein.
- (xii) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:9 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6 or a derivative,
- 25 homologue, analogue, chemical equivalent or mimetic of said protein.
- (xiii) a protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in ~~<400>~~SEQ ID NO:1 or a derivative,
- 30 homologue or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:2 or a derivative, homologue or mimetic thereof or an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:2.

- (xiv) a protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in ~~<400>~~SEQ ID NO:3 or a derivative, homologue or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:4 or a derivative, homologue or mimetic thereof or an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:4.
- (xv) a protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in ~~<400>~~SEQ ID NO:5 or a derivative, homologue or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:6 or a derivative, homologue or mimetic thereof or an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6.
- (xvi) a protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in ~~<400>~~SEQ ID NO:7 or a derivative, homologue or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:8 or a derivative, homologue or mimetic thereof or an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:8.
- (xvii) a protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in ~~<400>~~SEQ ID NO:9 or a derivative, homologue or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:6 or a derivative, homologue or mimetic thereof or an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6.
- (xviii) a protein as defined in any one of paragraphs (i) to (xvii) in a homodimeric form.

(xix) a protein as defined in any one of paragraphs (i) to (xvii) in a heterodimeric form.

The present invention contemplates therapeutic and prophylactic uses of B38, B55 and
5 B60 amino acid and nucleic acid molecules, in addition to B38, B55 and B60 agonistic and
antagonistic agents.

The present invention contemplates a method of modulating expression of *B38*, *B55*
and/or *B60* in a mammal, said method comprising contacting the *B38*, *B55* and/or *B60*
10 gene with an effective amount of an agent for a time and under conditions sufficient to
upregulate, downregulate or otherwise modulate expression of *B38*, *B55* and/or *B60*.

Another aspect of the present invention contemplates a method of modulating activity of
B38, *B55* and/or *B60* in a subject, said method comprising administering to said subject a
15 modulating effective amount of an agent for a time and under conditions sufficient to
increase or decrease *B38*, *B55* and/or *B60* activity.

Still another aspect of the present invention relates to a method of treating a mammal
suffering from a condition characterised by one or more symptoms of obesity, anorexia,
20 diabetes and/or energy imbalance said method comprising administering to said mammal
an effective amount of an agent for a time and under conditions sufficient to modulate the
expression of *B38*, *B55* and/or *B60* or sufficient to modulate the activity of *B38*, *B55*
and/or *B60*.

In another aspect the present invention relates to a method of treating a mammal suffering
25 from a disease condition characterised by one or more symptoms of obesity, anorexia,
diabetes or energy imbalance said method comprising administering to said mammal an
effective amount of *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60*.

In another aspect, the present invention contemplates a pharmaceutical composition
30 comprising a modulator of *B38*, *B55* and/or *B60* expression or *B38*, *B55* and/or *B60*
activity and one or more pharmaceutically acceptable carriers and/or diluents.

In yet another aspect the pharmaceutical composition comprises B38, B55 and/or B60 or *B38*, *B55* and/or *B60* or a derivative, homologue, analogue, chemical equivalent or mimetic thereof and one or more pharmaceutically acceptable carriers and/or diluents.

- 5 Still another aspect of the present invention is directed to antibodies to B38, B55 and/or B60 or *B38*, *B55* and/or *B60* including catalytic antibodies.

- Yet another aspect of the present invention contemplates a method for detecting B38, B55 and/or B60 or *B38*, *B55* and/or *B60* mRNA in a biological sample from a subject said
- 10 method comprising contacting said biological sample with an antibody specific for B38, B55 and/or B60 or *B38*, *B55* and/or *B60* mRNA or its derivatives or homologs for a time and under conditions sufficient for a complex to form, and then detecting said complex. Such methods may be particularly useful for the diagnosis of the development of or predisposition to obesity, anorexia, diabetes or energy imbalance.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the amino acid sequence of B55 in the Israeli sand rat (ISR), mouse, rat and human. Mouse, rat and human sequences were deduced from 3, 5 and 8 expressed sequence tags (ESTs), respectively. No rat EST was found which covered the 5' and 3' region of the protein. Dashes indicate homology to the ISR sequence, and forward slashes indicate a deletion.

Figure 2 **Figure 2(i)** is a graphical representation of the levels of B55 gene expression in the liver and **Figure 2(ii)** is a graphical representation of the levels of B55 gene expression in adipose tissue of fed and fasted animals of groups A, B and C. Gene expression levels were determined by Real Time PCR of cDNA, relative to the house-keeping gene β -actin.

~~**Figure 3**~~ **Figure 3(i), 3(ii) and 3(iii)** ~~is a~~ are graphical representation-representations of B60 gene expression in the liver versus body weight with all animals together and in individual groups (top) and B60 gene expression in the muscle of fasted animals versus body weight and insulin (bottom). Gene expression levels were determined by Real Time PCR of cDNA, relative to the house-keeping gene β -actin.

~~**Figure 4**~~ **Figure 4(i), 4(ii) and 4(iii)** ~~is a~~ are graphical representation-representations of B38 gene expression in the liver versus body weight with all animals together and in individual groups (top) and B38 gene expression in the liver and adipose tissue versus blood triglyceride levels. Gene expression levels were determined by Real Time PCR of cDNA, relative to the house-keeping gene β -actin.

Figure 5 is a schematic representation of the genomic structure of the human B55 gene.

~~**Figure 6**~~ **Figures 6(i), 6(ii), 6(iii), 6(iv), 6(v) and 6(vi)** ~~is a~~ are schematic representation representations of the human B55 gene <400>SEQ ID NO:9 showing the transcription initiation and termination sites and the intron/exon boundaries.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated, in part, on the identification of novel genes which are differentially expressed in association with obesity, diabetes and energy metabolism.

5

Accordingly, one aspect of the present invention provides an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a protein or a derivative, homologue or mimetic of said protein wherein said nucleic acid molecule is differentially expressed in
10 liver tissue of obese animals compared to lean animals.

In another aspect, the present invention provides an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a protein or a derivative, homologue or mimetic of
15 said protein wherein said nucleic acid molecule is differentially expressed in liver tissue of fed animals compared to fasted animals.

The terms "lean" and "obese" are used in their most general sense but should be considered relative to the standard criteria for determining obesity. Generally, for human
20 subjects the definition of obesity is BMI > 30 (Risk Factor Prevalence 1990; Waters and Bennett, 1995).

The term "fasted" should be understood to mean that an animal is deprived of food. Preferably, the animal is fasted for at least 24 hours.

25

Conveniently, an animal model may be employed to study the physiology of obese and lean animals. In particular, the present invention is exemplified using the *Psammomys obesus* (the Israeli sand rat) an animal model of dietary-induced obesity and NIDDM. In its natural desert habitat, an active lifestyle and saltbush diet ensure that it remains lean
30 and normoglycemic (Shafrir and Gutman, 1993). However, in a laboratory setting on a diet of *ad libitum* chow (on which many other animal species remain healthy), a range of pathophysiological responses are seen (Barnett *et al*, 1994a, b; Barnett *et al*, 1995). By the age of 16 weeks, more than half of the animals become obese and approximately one third develop NIDDM. Only hyperphagic animals go on to develop hyperglycemia,

highlighting the importance of excessive energy intake in the pathophysiology of obesity and NIDDM in *Psammomys obesus* (Collier *et al*, 1997a; Walder *et al*, 1997a). Other phenotypes found include hyperinsulinemia, dyslipidemia, impaired glucose tolerance, cataracts and atherosclerosis (Collier *et al*, 1997a, b). *Psammomys obesus* exhibit a range of bodyweight and blood glucose and insulin levels which forms a continuous curve that closely resembles the patterns found in human populations, including the inverted U-shaped relationship between blood glucose and insulin levels known as "Starling's curve of the pancreas" (Barnett *et al*, 1994a; DeFronzo, 1988). It is the heterogeneity of the phenotypic response of *Psammomys obesus* which make it an ideal model to study the etiology and pathophysiology of obesity and NIDDM.

Another aspect of the present invention provides an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:2 or a derivative, homologue or mimetic thereof or having at least about 45% similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:2.

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. The percentage similarity may be greater than 50% such as at least 70% or at least 80% or at least 90% or at least 95% or higher.

More particularly, the present invention contemplates an isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:1 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:1 under low stringency conditions.

Reference herein to a low stringency includes and encompasses from at least about 0% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium

5 stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt

10 for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions. Stringency may be measured using a range of temperature such as from about 40°C to about 65°C. Particularly useful stringency conditions are at 42°C. In general, washing is carried out at $T_m = 69.3 + 0.41 (G + C) \% [19] = [-12^\circ\text{C}]-12^\circ\text{C}$. However, the T_m of a duplex DNA decreases by $[1^\circ\text{C}]1^\circ\text{C}$ with every increase of 1% in

15 the number of mismatched based pairs (Bonner *et al* 1973).

Preferably, the present invention contemplates a nucleic acid molecule or a derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:1 or a derivative or homologue thereof or capable of hybridising

20 to <400>SEQ ID NO:1 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>SEQ ID NO:2 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:2.

25 More particularly, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:1.

In another aspect the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a

30 nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:4 or a derivative, homologue or mimetic thereof or having at least about 45% similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:4.

More particularly, the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:3 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:3 under low stringency conditions.

5

Preferably, the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:3 or a derivative or homologue thereof or capable of hybridising to <400>SEQ ID NO:3 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>SEQ ID NO:4 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:4.

10

More particularly, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:3.

15

In yet another aspect, the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:6 or a derivative, homologue or mimetic thereof or having at least about 45% similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

20

More particularly, the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:5 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:5 under low stringency conditions.

25

Preferably, the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:5 or a derivative, homologue or mimetic thereof or capable of hybridising to <400>SEQ ID NO:5 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in

30

<400>SEQ ID NO:6 or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

More particularly, the present invention contemplates a nucleic acid molecule comprising
5 a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:5.

In yet another aspect, the present invention provides a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid
10 sequence substantially as set forth in <400>SEQ ID NO:8 or a derivative, homologue or mimetic thereof or having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:8.

More particularly, the present invention contemplates a nucleic acid molecule or
15 derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:7 or a derivative or homologue thereof, or capable of hybridising to <400>SEQ ID NO:7 under low stringency conditions.

Preferably, the present invention contemplates a nucleic acid molecule or derivative,
20 homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>SEQ ID NO:7 or a derivative, homologue or mimetic thereof or capable of hybridising to <400>SEQ ID NO:7 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in
<400>SEQ ID NO:8 or a sequence having at least about 45 % similarity to at least 10
25 contiguous amino acids in <400>SEQ ID NO:8.

More particularly, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>SEQ ID NO:7.

In yet another aspect, the present invention provides a nucleic acid molecule or derivative,
30 homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>SEQ ID NO:6 or a derivative, homologue or mimetic thereof or having at least about 45 % similarity to at least 10 contiguous amino acids in <400>SEQ ID NO:6.

More particularly, the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:9 or a derivative or homologue thereof, or capable of hybridising to ~~<400>~~SEQ ID NO:9 under low stringency conditions.

Preferably, the present invention contemplates a nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:9 or a derivative, homologue or mimetic thereof or capable of hybridising to ~~<400>~~SEQ ID NO:9 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in ~~<400>~~SEQ ID NO:6 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6.

More particularly, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in ~~<400>~~SEQ ID NO:9.

The nucleic acid molecules according to these aspects of the present invention correspond herein to B38, B55 and B60. The expression pattern of these genes has been determined, *inter alia*, to indicate an involvement in the regulation of one or more of obesity, diabetes and/or energy metabolism. In addition to the differential expression of B38, B55 and B60 in the liver tissue of lean vs obese animals and fed vs fasted animals these genes are also expressed in other tissues including, but in no way limited to, muscle and hypothalamus. Reference to "B38, B55 and B60" in italicised text should be understood as a reference to the nucleic acid molecule while reference to "B38, B55 and B60" in non-italicised text should be understood as a reference to the expression product. Murine B38 comprises the amino acid sequence set forth in ~~<400>~~SEQ ID NO:2 and the cDNA sequence set forth in ~~<400>~~SEQ ID NO:1. Murine B55 comprises the amino acid sequence set forth in ~~<400>~~SEQ ID NO:4 and the cDNA sequence set forth in ~~<400>~~SEQ ID NO:3. Human B55 comprises the amino acid sequence set forth in ~~<400>~~SEQ ID NO:6 and the cDNA sequence set forth in ~~<400>~~SEQ ID NO:5. The genomic sequence of human B55 is provided in ~~<400>~~SEQ ID NO:9. Murine B60 comprises the amino acid sequence set forth in ~~<400>~~SEQ ID NO:8 and the cDNA sequence set forth in ~~<400>~~SEQ ID NO:7. The nucleic acid molecule encoding B38, B55 or B60 is preferably

a sequence of deoxyribonucleic acids such as a cDNA sequence or a genomic sequence. A genomic sequence may also comprise exons and introns. A genomic sequence may also include a promoter region or other regulatory regions. It should be understood that the genomic sequence disclosed herein in <400>SEQ ID NO:9 corresponds only to that part
5 of the sequence running from the transcription initiation site to the transcription termination site. Accordingly, the <400>SEQ ID NO:9 sequence and other genomic sequences encompassed by the present invention may comprise either more or less sequence than that encompassed from the transcription initiation site to the transcription termination site. For example, it may comprise additional nontranslated sequences such
10 as regulatory sequences located up- or down- stream of the transcription start/stop sites.

Another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:1
15 or a derivative or homologue thereof under low stringency conditions at 42°C.

Yet another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:3 or a derivative or homologue thereof under low stringency conditions at 42°C.

20 Still another aspect of the present invention contemplates a genomic nucleic acid molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:7 or a derivative or homologue thereof under low stringency conditions at 42°C.

Still yet another aspect of the present invention contemplates a genomic nucleic acid
25 molecule or derivative homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:5 or a derivative or homologue thereof under low stringency conditions.

Yet another aspect of the present invention contemplates a cDNA nucleic acid molecule or
30 derivative, homologue or analogue thereof capable of hybridising to <400>SEQ ID NO:9 or a derivative or homologue thereof under low stringency conditions.

Reference herein to "B38, B55, B60" and "*B38, B55, B60*" should be understood as a reference to all forms of these molecules and derivatives, homologues, analogues,

chemical equivalents and mimetics thereof including, for example, any peptide and cDNA isoforms which arise from alternative splicing of *B38*, *B55* or *B60* mRNA or mutants or polymorphic variants of *B38*, *B55*, *B60* or *B38*, *B55*, *B60*.

- 5 The molecules disclosed herein have been isolated from the Israeli sand rat. However, it should be understood that the protein and/or gene molecules may also be isolated from any other human or non-human species.

- Derivatives include fragments, parts, portions, mutants, variants and mimetics from
10 natural, synthetic or recombinant sources including fusion proteins. Parts or fragments include, for example, active regions of *B38*, *B55* or *B60*. Derivatives may be derived from insertion, deletion or substitution of amino acids. Amino acid insertional derivatives include amino and/or carboxylic terminal fusions as well as intrasequence insertions of
15 single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterized by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. An
20 example of substitutional amino acid variants are conservative amino acid substitutions. Conservative amino acid substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Additions to amino acid sequences include fusions with other
25 peptides, polypeptides or proteins.

- Chemical and functional equivalents of *B38*, *B55*, *B60* or *B38*, *B55*, *B60* should be understood as molecules exhibiting any one or more of the functional activities of these molecules and may be derived from any source such as being chemically synthesized or
30 identified via screening processes such as natural product screening.

The derivatives include fragments having particular epitopes or parts of the entire protein fused to peptides, polypeptides or other proteinaceous or non-proteinaceous molecules.

Analogues contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecules or their analogues.

5

Derivatives of nucleic acid sequences may similarly be derived from single or multiple nucleotide substitutions, deletions and/or additions including fusion with other nucleic acid molecules. The derivatives of the nucleic acid molecules of the present invention include oligonucleotides, PCR primers, antisense molecules, molecules suitable for use in
10 cosuppression and fusion of nucleic acid molecules. Derivatives of nucleic acid sequences also include degenerate variants.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an
15 aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

20

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

25 The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of
30 a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration
5 with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carboethoxylation with diethylpyrocarbonate.

10

Examples of incorporating unnatural amino acids and derivatives during protein synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl
15 alanine and/or D-isomers of amino acids. A list of unnatural amino acids contemplated herein is shown in Table 1.

TABLE 1

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane- carboxylate	Cpro	L-N-methylasparagine	Nmasn
			L-N-methylaspartic acid	Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl- carboxylate	Norb	L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
15	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Das	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
30	D-threonine	Dthr	L-norleucin	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab

	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
5	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
10	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
15	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
20	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
25	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
30	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe

	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
5	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
10	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
15	L- α -methylhistidine	Mhis	L- α -methylhomophenyl	Mhphe
			alanine	
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
20	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
25	L- α -methylvaline	Mval	L-N-methylhomophenyl	Nmhphe
			alanine	
	N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
	carbamylmethyl)glycine		carbamylmethyl)glycine	
30	1-carboxy-1-(2,2-diphenyl-Nmbc			
	ethylamino)cyclopropane			

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety.

The nucleic acid molecule of the present invention is preferably in isolated form or ligated to a vector, such as an expression vector. By "isolated" is meant a nucleic acid molecule having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject nucleic acid molecule, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject nucleic acid molecule relative to other components as determined by molecular weight, encoding activity, nucleotide sequence, base composition or other convenient means. The nucleic acid molecule of the present invention may also be considered, in a preferred embodiment, to be biologically pure.

The term "protein" should be understood to encompass peptides, polypeptides and proteins. The protein may be glycosylated or unglycosylated and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins. Reference hereinafter to a "protein" includes a protein comprising a sequence of amino acids as well as a protein associated with other molecules such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.

In a particularly preferred embodiment, the nucleotide sequence corresponding to *B38* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:1 or a derivative, homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:1.

In another particularly preferred embodiment, the nucleotide sequence corresponding to *B55* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:3 or a derivative, homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:3.

In still another particularly preferred embodiment, the nucleotide sequence corresponding to *B55* is a cDNA sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:5 or a derivative homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:5.

In yet another preferred embodiment, the nucleotide sequence corresponding to *B55* is a genomic sequence comprising a sequence of nucleotides as set forth in <400>SEQ ID NO:9 or a derivative homologue or analogue thereof including a nucleotide sequence
5 having similarity to <400>SEQ ID NO:9.

In yet another particularly preferred embodiment, the nucleotide sequence corresponding to *B60* is a cDNA sequence comprising a sequence of nucleotides as set forth in
10 <400>SEQ ID NO:7 or a derivative, homologue or analogue thereof including a nucleotide sequence having similarity to <400>SEQ ID NO:7.

A derivative of the nucleic acid molecule of the present invention also includes a nucleic acid molecule capable of hybridising to a nucleotide sequence as set forth in any one or more of <400>SEQ ID NO: 1, <400>SEQ ID NO:3, <400>SEQ ID NO:5,
15 <400>SEQ ID NO:7 or <400>SEQ ID NO:9 under low stringency conditions. Preferably, low stringency is at 42°C.

The nucleic acid molecule may be ligated to an expression vector capable of expression in a prokaryotic cell (e.g. *E.coli*) or a eukaryotic cell (e.g. yeast cells, fungal cells,
20 insect cells, mammalian cells or plant cells). The nucleic acid molecule may be ligated or fused or otherwise associated with a nucleic acid molecule encoding another entity such as, for example, a signal peptide. It may also comprise additional nucleotide sequence information fused, linked or otherwise associated with it either at the 3' or 5' terminal portions or at both the 3' and 5' terminal portions. The nucleic acid molecule
25 may also be part of a vector, such as an expression vector. The latter embodiment facilitates production of recombinant forms of sphingosine kinase which forms are encompassed by the present invention.

The present invention extends to the expression product of the nucleic acid molecules as
30 hereinbefore defined.

Expression products are *B38*, *B55* and *B60* having an amino acid sequence as set forth in <400>SEQ ID NO:2, <400>SEQ ID NO:4, <400>SEQ ID NO:6 and <400>SEQ ID NO:8, respectively, or are derivatives, analogues, homologues, chemical equivalents

or mimetics thereof as defined above or are derivatives or mimetics having an amino acid sequence of at least about 45 % similarity to at least 10 contiguous amino acids in the amino acid sequence set forth in ~~<400>~~SEQ ID NO:2, ~~<400>~~SEQ ID NO:4, ~~<400>~~SEQ ID NO:6 and ~~<400>~~SEQ ID NO:8, respectively, or a derivative or
5 mimetic thereof.

Another aspect of the present invention is directed to an isolated protein selected from the list consisting of:

- 10 (i) a protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in liver tissue of obese animals compared to lean animals or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.
- (ii) a protein encoded by a novel nucleic acid molecule which molecule is
15 differentially expressed in liver tissue of fed animals compared to fasted animals or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.
- (iii) B38, B55 or B60 or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.
20
- (iv) a protein having an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:2 or a derivative, homologue or mimetic thereof or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:2 or a derivative, homologue, analogue, chemical equivalent or mimetic
25 of said protein.
- (v) a protein having an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:4 or a derivative, homologue or mimetic thereof or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:4 or a derivative, homologue, analogue, chemical equivalent or mimetic
30 of said protein.
- (vi) a protein having an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:6 or a derivative, homologue or mimetic thereof or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ

ID NO:6 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

- 5 (vii) a protein having an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:8 or a derivative, homologue or mimetic thereof or a sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:8 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- 10 (viii) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:1 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:2 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- 15 (ix) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:3 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:4 or a derivative,
- 20 homologue, analogue, chemical equivalent or mimetic of said protein.
- (x) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:5 or a derivative, homologue or analogue thereof or a sequence encoding an amino acid sequence having at least about 45 % similarity to
- 25 at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.
- (xi) a protein encoded by a nucleotide sequence substantially as set forth in ~~<400>~~SEQ ID NO:7 or a derivative, homologue or analogue thereof or a
- 30 sequence encoding an amino acid sequence having at least about 45 % similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:8 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

- (xii) a protein encoded by a nucleotide sequence substantially as set forth in
5 <400>SEQ ID NO:9 or a derivative, homologue or analogue thereof or a
sequence encoding an amino acid sequence having at least about 45 % similarity to
at least 10 contiguous amino acids in <400>SEQ ID NO:6 or a derivative,
homologue, analogue, chemical equivalent or mimetic of said protein.
- (xiii) a protein encoded by a nucleic acid molecule capable of hybridising to the
nucleotide sequence as set forth in <400>SEQ ID NO:1 or a derivative,
homologue or analogue thereof under low stringency conditions and which
10 encodes an amino acid sequence substantially as set forth in <400>SEQ ID
NO:2 or a derivative, homologue or mimetic thereof or an amino acid sequence
having at least about 45 % similarity to at least 10 contiguous amino acids in
<400>SEQ ID NO:2.
- (xiv) a protein encoded by a nucleic acid molecule capable of hybridising to the
nucleotide sequence as set forth in <400>SEQ ID NO:3 or a derivative,
homologue or analogue thereof under low stringency conditions and which
encodes an amino acid sequence substantially as set forth in <400>SEQ ID
15 NO:4 or a derivative, homologue or mimetic thereof or an amino acid sequence
having at least about 45 % similarity to at least 10 contiguous amino acids in
20 <400>SEQ ID NO:4.
- (xv) a protein encoded by a nucleic acid molecule capable of hybridising to the
nucleotide sequence as set forth in <400>SEQ ID NO:5 or a derivative,
homologue or analogue thereof under low stringency conditions and which
25 encodes an amino acid sequence substantially as set forth in <400>SEQ ID
NO:6 or a derivative, homologue or mimetic thereof or an amino acid sequence
having at least about 45 % similarity to at least 10 contiguous amino acids in
30 <400>SEQ ID NO:6.
- (xvi) a protein encoded by a nucleic acid molecule capable of hybridising to the
nucleotide sequence as set forth in <400>SEQ ID NO:7 or a derivative,
homologue or analogue thereof under low stringency conditions and which
encodes an amino acid sequence substantially as set forth in <400>SEQ ID

NO:8 or a derivative, homologue or mimetic thereof or an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:8.

- 5 (xvii) a protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in ~~<400>~~SEQ ID NO:9 or a derivative, homologue or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in ~~<400>~~SEQ ID NO:6 or a derivative, homologue or mimetic thereof or an amino acid sequence
10 having at least about 45% similarity to at least 10 contiguous amino acids in ~~<400>~~SEQ ID NO:6.
- (xviii) a protein as defined in any one of paragraphs (i) to (xvii) in a homodimeric form.
- 15 (xix) a protein as defined in any one of paragraphs (i) to (xvii) in a heterodimeric form.

The protein of the present invention is preferably in isolated form. By "isolated" is meant a protein having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject protein,
20 preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject protein relative to other components as determined by molecular weight, amino acid sequence or other convenient means. The protein of the present invention may also be considered, in a preferred embodiment, to
25 be biologically pure.

Without limiting the theory or mode of action of the present invention, the expression of B38 is thought to relate to body weight and circulating triglycerides. Modulation of B38 expression is thought, *inter alia*, to regulate energy balance via effects on energy intake
30 and also effects on carbohydrate/fat metabolism. The energy intake effects are likely to be mediated via the central nervous system but peripheral effects on the metabolism of both carbohydrate and fat are possible. The expression of B55 is thought to be regulated by fasting and feeding, accordingly, regulating the expression and/or activity of this gene or its expression product could provide a mechanism for regulating both body weight and

energy metabolism, including carbohydrate and fat metabolism. Since B55 is differentially regulated in diabetes, it is also thought to provide a diabetic target. Finally, B60 gene expression has been shown to associate with body weight. In this regard, B60 is thought to exhibit similar effects to B38. To the extent that it is not specified, reference to B38, B55, B60 or *B38*, *B55*, *B60* includes reference to derivatives, homologs, analogs, chemical equivalents and mimetics thereof. For example, reference to B38 and chemical equivalents thereof should be understood to encompass the complement components C3a and C5a which comprise a region of high homology with B38. These molecules comprise an anaphylatoxin-like domain and have been shown to increase hepatic glucose output.

Accordingly, regulating the functional activity and/or levels of these molecules provides a mechanism for the therapeutic and prophylactic treatment of conditions such as obesity, anorexia, energy imbalance and diabetes. The cloning and sequencing of these genes and expression products now provides further molecules for use in such treatments. These molecules may also be useful in the agricultural industry to assist in the generation of leaner animals, or where required, of obese animals. Accordingly, the mammal contemplated by the present invention includes, but is not limited to, humans, primates, livestock animals (e.g. pigs, sheep, cows, horses, donkeys), laboratory test animals (e.g. mice, rats, guinea pigs, hamsters, rabbits), companion animals (e.g. dogs, cats) and captured wild animals (e.g. foxes, kangaroos and deer). A particularly preferred mammal is a human, primate or livestock animal.

Accordingly, the present invention contemplates therapeutic and prophylactic uses of B38, B55 and B60 amino acid and nucleic acid molecules, in addition to B38, B55 and B60 agonistic and antagonistic agents.

The present invention contemplates, therefore, a method of modulating expression of *B38*, *B55* and/or *B60* in a mammal, said method comprising contacting the *B38*, *B55* and/or *B60* gene with an effective amount of an agent for a time and under conditions sufficient to upregulate, downregulate or otherwise modulate expression of *B38*, *B55* and/or *B60*. For example, antisense sequences such as oligonucleotides may be utilised.

Conversely, nucleic acid molecules encoding B38, B55 and/or B60 or derivatives thereof may be introduced to upregulate one or more specific functional activities.

Another aspect of the present invention contemplates a method of modulating activity of
5 B38, B55 and/or B60 in a subject, said method comprising administering to said subject a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease B38, B55 and/or B60 activity.

Modulation of said activity by the administration of an agent to a mammal can be
10 achieved by one of several techniques, including but in no way limited to introducing into said mammal a proteinaceous or non-proteinaceous molecule which:

- (i) modulates expression of *B38*, *B55* and/or *B60* ;
- 15 (ii) functions as an antagonist of B38, B55 and/or B60;
- (iii) functions as an agonist of B38, B55 and/or B60.

Said proteinaceous molecule may be derived from natural or recombinant sources
20 including fusion proteins or following, for example, natural product screening. Said non-proteinaceous molecule may be, for example, a nucleic acid molecule or may be derived from natural sources, such as for example natural product screening or may be chemically synthesised. The present invention contemplates chemical analogues of B38, B55 and/or B60 or small molecules capable of acting as agonists or antagonists.
25 Chemical agonists may not necessarily be derived from B38, B55 and/or B60 but may share certain conformational similarities. Alternatively, chemical agonists may be specifically designed to mimic certain physiochemical properties. Antagonists may be any compound capable of blocking, inhibiting or otherwise preventing B38, B55 and/or B60 from carrying out their normal biological functions. Antagonists include
30 monoclonal antibodies and antisense nucleic acids which prevent transcription or translation of *B38*, *B55* and/or *B60* genes or mRNA in mammalian cells. Modulation of expression may also be achieved utilising antigens, RNA, ribosomes, DNazymes, RNA aptamers or antibodies.

Said proteinaceous or non-proteinaceous molecule may act either directly or indirectly to modulate the expression of *B38*, *B55* and/or *B60* or the activity of *B38*, *B55* and/or *B60*. Said molecule acts directly if it associates with *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60* to modulate expression or activity. Said molecule acts indirectly if it associates with
5 a molecule other than *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60* which other molecule either directly or indirectly modulates the expression or activity of *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60*. Accordingly, the method of the present invention encompasses the regulation of *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60* expression or activity via the induction of a cascade of regulatory steps.

10

The molecules which may be administered to a mammal in accordance with the present invention may also be linked to a targeting means such as a monoclonal antibody, which provides specific delivery of these molecules to the target cells.

15 A further aspect of the present invention relates to the use of the invention in relation to mammalian disease conditions. For example, the present invention is particularly useful, but in no way limited to, use in a therapeutic or prophylactic treatment of obesity, anorexia, diabetes or energy imbalance.

Accordingly, another aspect of the present invention relates to a method of treating a
20 mammal suffering from a condition characterised by one or more symptoms of obesity, anorexia, diabetes and/or energy imbalance said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *B38*, *B55* and/or *B60* or sufficient to modulate the activity of *B38*, *B55* and/or *B60*.

25

In another aspect the present invention relates to a method of treating a mammal suffering from a disease condition characterised by one or more symptoms of obesity, anorexia, diabetes or energy imbalance said method comprising administering to said mammal an effective amount of *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60*.

30

~~An effective amount~~ An "effective amount" means an amount necessary at least partly to attain the desired immune response, or to delay the onset or inhibit progression or halt altogether, the onset or progression of a particular condition of the individual to be treated, the taxonomic group of the individual to be treated, the degree of protection

desired, the formulation of the vaccine, the assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

- 5 In accordance with these methods, B38, B55 and/or B60 or *B38*, *B55* and/or *B60* or agents capable of modulating the expression or activity of said molecules may be coadministered with one or more other compounds or other molecules. By "coadministered" is meant simultaneous administration in the same formulation or in two different formulations via the same or different routes or sequential administration by the same or different routes. By "sequential" administration is meant a time difference of from seconds, minutes, hours or days between the administration of the two types of molecules. These molecules may be administered in any order.

- 15 In yet another aspect the present invention relates to the use of an agent capable of modulating the expression of *B38*, *B55* and/or *B60* or a derivative, homologue or analogue thereof in the manufacture of a medicament for the treatment of a condition characterised by obesity, anorexia, diabetes and/or energy imbalance.

- 20 In still yet another aspect the present invention relates to the use of an agent capable of modulating the activity of B38, B55 and/or B60 or a derivative, homologue, analogue, chemical equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a condition characterised by obesity, anorexia, diabetes and/or energy imbalance.

- 25 A further aspect of the present invention relates to the use of *B38*, *B55* and/or *B60* or derivative, homologue or analogue thereof or B38, B55 and/or B60 or derivative, homologue, analogue, chemical equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a condition characterised by obesity, anorexia, diabetes and/or energy imbalance.

30

Still yet another aspect of the present invention relates to agents for use in modulating the expression of *B38*, *B55* and/or *B60* or a derivative, homologue or analogue thereof.

A further aspect relates to agents for use in modulating B38, B55 and/or B60 activity or a derivative, homologue, analogue, chemical equivalent or mimetic thereof.

5 Still another aspect of the present invention relates to *B38*, *B55* and/or *B60* or derivative, homologue or analogue thereof or B38, B55 and/or B60 or derivative, homologue, analogue, chemical equivalent or mimetic thereof for use in treating a condition characterised by one or more symptoms of obesity, anorexia, diabetes and/or energy imbalance.

10 In a related aspect of the present invention, the mammal undergoing treatment may be a human or an animal in need of therapeutic or prophylactic treatment.

In another aspect, the present invention contemplates a pharmaceutical composition comprising a modulator of B38, B55 and/or B60 expression or B38, B55 and/or B60 activity and one or more pharmaceutically acceptable carriers and/or diluents. In another
15 embodiment, the pharmaceutical composition comprises B38, B55 and/or B60 or *B38*, *B55* and/or *B60* or a derivative, homologue, analogue, chemical equivalent or mimetic thereof and one or more pharmaceutically acceptable carriers and/or diluents. For brevity, all such components of such a composition are referred to as "active components".

20

The compositions of active components in a form suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable
25 under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

The carrier can be a solvent or other medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the
30 like), suitable mixtures thereof, and vegetable oils.

The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic

agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

- 5 Sterile injectable solutions are prepared by incorporating the active components in the required amount in the appropriate solvent with optionally other ingredients, as required, followed by sterilization by, for example, filter sterilization, irradiation or other convenient means. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying
10 technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

When the active components are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed
15 in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active
20 compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between
25 about 0.1 μ g and 2000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic
30 acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the

dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should
5 be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents,
10 dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the
15 compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be
20 treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of
25 compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

The principal active component may be compounded for convenient and effective
30 administration in sufficient amounts with a suitable pharmaceutically acceptable carrier in dosage unit form. A unit dosage form can, for example, contain the principal active component in amounts ranging from 0.5 μ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 μ g to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active

ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

In general terms, effective amounts will range from 0.01 ng/kg/body weight to above
5 10,000 mg/kg/body weight. Alternative amounts range from 0.1 ng/kg/body weight to above 1000 mg/kg/body weight.

The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule
10 capable of expressing the active ingredients or modulating the expression of the active ingredients or activity. The vector may, for example, be a viral vector.

Still another aspect of the present invention is directed to antibodies to B38, B55 and/or B60 or *B38*, *B55* and/or *B60* (herein referred to as "the immunogen") including catalytic
15 antibodies. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies or may be specifically raised. In the case of the latter, the immunogen may first need to be associated with a carrier molecule. The antibodies of the present invention are particularly useful as therapeutic or diagnostic agents.
Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore,
20 the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies. The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a diagnostic tool, for example, for monitoring the program of a therapeutic regime.

25 For example, specific antibodies can be used to screen for the immunogen. The latter would be important, for example, as a means for screening for levels of the immunogen in a cell extract or other biological fluid or purifying sphingosine kinase made by recombinant means from culture supernatant fluid. Techniques for the assays
30 contemplated herein are known in the art and include, for example, sandwich assays, ELISA and flow cytometry.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed

above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of the immunogen.

5

Both polyclonal and monoclonal antibodies are obtainable by immunization with the immunogen or derivatives and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal
10 with an effective amount of the immunogen or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoabsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

15

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic
20 preparation can be done by techniques which are well known to those who are skilled in the art. (See, for example Douillard and Hoffman, Basic Facts about Hybridomas, in *Compendium of Immunology* Vol II, ed. by Schwartz, 1981; Kohler and Milstein, *Nature* 256: 495-499, 1975; *European Journal of Immunology* 6: 511-519, 1976).

25 In another aspect of the present invention, the molecules of the present invention are also useful as screening targets for use in applications such as the diagnosis of disorders which are regulated by B38, B55 and/or B60 or B38, B55 and/or B60.

Yet another aspect of the present invention contemplates a method for detecting B38, B55 and/or B60 or B38, B55 and/or B60 mRNA in a biological sample from a subject
30 said method comprising contacting said biological sample with an antibody specific for B38, B55 and/or B60 or B38, B55 and/or B60 mRNA or its derivatives or homologs for a time and under conditions sufficient for a complex to form, and then detecting said

complex. Such methods may be particularly useful for the diagnosis of the development of or predisposition to obesity, anorexia, diabetes or energy imbalance.

5 The presence of B38, B55 and/or B60 may be determined in a number of ways such as by Western blotting, ELISA or flow cytometry procedures. *B38, B55 and/or B60* mRNA may be detected, for example, by *in situ* hybridization or Northern blotting. These, of course, include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

10

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody.

15 20 Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain B38, B55 and/or B60 or *B38, B55 and/or B60* including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

25 30

In the typical forward sandwich assay, a first antibody having specificity for the B38, B55 and/or B60 or *B38, B55 and/or B60* or antigenic parts thereof, is either covalently

- or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an
- 5 immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes) and under suitable conditions (e.g. 25°C) to allow binding of any subunit
- 10 present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.
- 15 An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the
- 20 first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the

25 detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

30

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish

peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. "Reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength and the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The present invention also contemplates genetic assays such as involving PCR analysis to detect *B38*, *B55* and/or *B60* or its derivatives. Genetic assays directed to detecting *B38*, *B55* and/or *B60* have a wide variety of applications including, but not limited to, diagnosing disorders involving aberrant expression of one or more of these molecules or expression of specific polymorphic variants or isoforms of these molecules. Such assays may also be utilised to genetically screen individuals for the purpose of assessing the

existence of a predisposition to the development of such disorders. For example, to detect the expression of given genetic polymorphic forms of any one of *B38*, *B55* and/or *B60*, or the existence of specific haplotypes of these genes. In this regard, by determining gene expression patterns a mechanism is provided for designing treatment
5 strategies appropriate for the subject individual.

The present invention should also be understood to extend to methods of diagnosing or monitoring a disease condition in a mammal, which disease condition is characterised by aberrant *B38*, *B55* and/or *B60* expression or functional activity, said method comprising
10 screening for *B38*, *B55* and/or *B60* or *B38*, *B55* and/or *B60* in a biological sample from said mammal.

Further features of the present invention are more fully described in the following non-limiting Examples.

SUMMARY OF SEQUENCE ID NOS

A summary of sequence identity numbers used throughout the subject specification are provided in Table 2.

5

TABLE 2

<400>SEQ ID NO:	DESCRIPTION
<400>SEQ ID NO:1	cDNA Nucleotide sequence of murine B38
<400>SEQ ID NO:2	Amino acid sequence of murine B38
<400>SEQ ID NO:3	cDNA Nucleotide sequence of murine B55
<400>SEQ ID NO:4	Amino acid sequence of murine B55
<400>SEQ ID NO:5	cDNA sequence of human B55
<400>SEQ ID NO:6	Amino acid sequence of human B55
<400>SEQ ID NO:7	cDNA Nucleotide sequence of murine B60
<400>SEQ ID NO:8	Amino acid sequence of murine B60
<400>SEQ ID NO:9	Genomic sequence of human B55
<400>SEQ ID NO:10	Primer sequence
<400>SEQ ID NO:11	Primer sequence
<400>SEQ ID NO:12	Primer sequence
<400>SEQ ID NO:13	Primer sequence
<400>SEQ ID NO:14	Primer sequence
<400>SEQ ID NO:15	Primer sequence
<400>SEQ ID NO:16	Primer sequence
<400>SEQ ID NO:17	Primer sequence
<400>SEQ ID NO:18	Fluorogenic probe sequence
<400>SEQ ID NO:19	Fluorogenic probe sequence

<400>SEQ ID NO:20

Fluorogenic probe sequence

<400>SEQ ID NO:21

Fluorogenic probe sequence

<400>SEQ ID NO:22

Expressed sequence tag

AMINO ACID ABBREVIATIONS

A summary of the single and three letter abbreviations for amino acid residues used in the present specification is provided in Table 3.

5

TABLE 3

Single and three letter amino acid abbreviations

10	Amino Acid	Three-letter Abbreviation	One-letter Symbol
	Alanine	Ala	A
	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic acid	Asp	D
15	Cysteine	Cys	C
	Glutamine	Gln	Q
	Glutamic acid	Glu	E
	Glycine	Gly	G
	Histidine	His	H
20	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
	Methionine	Met	M
	Phenylalanine	Phe	F
25	Proline	Pro	P
	Serine	Ser	S
	Threonine	The	T
	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
30	Valine	Val	V
	Any residue	Xaa	X

EXAMPLE 1

ANIMALS

A *Psammomys obesus* colony is maintained at Deakin University, with the breeding pairs
5 fed *ad libitum* a diet of lucerne and chow. Experimental animals were weaned at four
weeks of age and given a diet of standard laboratory chow from which 12% of energy
was derived from fat, 63% from carbohydrate and 25% from protein (Barastoc,
Pakenham, Australia). Animals were housed individually in a temperature controlled
room ($22 \pm 1^\circ\text{C}$) with a 12-12-hour light-dark cycle. At 18 weeks of age, animals were
10 sacrificed and the tissues immediately removed, frozen in liquid N_2 and then stored at -
 80°C .

For experimental purposes, *Psammomys obesus* can be classified into three groups
according to their blood glucose and plasma insulin concentration, taken in the fed state
15 at 16 weeks of age. Group A animals are normoglycemic (blood glucose $< 8.0 \text{ mmol/L}$)
and normoinsulinemic (plasma insulin $< 150 \text{ mU/L}$), Group B animals are
normoglycemic but hyperinsulinemic (plasma insulin $> 150 \text{ mU/L}$), and Group C animals
are hyperglycemic (blood glucose $> 150 \text{ mU/L}$) and hyperinsulinemic. The criteria for
the classification of animals into groups were based on those of Kalderon *et al.* 1986,
20 who first characterized the stages of development of the obesity/diabetes syndrome in
this species.

EXAMPLE 2

SEQUENCING AND CLONING OF B38, B55 AND B60

- 5 B38, B55 and B60 were all identified by differential display PCR using the RNAimage mRNA differential display system (GenHunter Corporation). Liver mRNA from fed and fasted, lean and obese *Psammomys obesus* was compared. The PCR products were separated on a 6% polyacrylamide gel, and differentially expressed PCR fragments were visualized by exposing the dried gel to x-ray film. Candidate bands were excised from the
- 10 gel and reamplified by PCR using the appropriate primer combination. Sequencing reactions were carried out using ABI PRISM Big-Dye terminator cycle sequencing ready reaction kits and analysed on an ABI 373A DNA sequencer. Gene database searches were performed at the National Centre for Biotechnology Information using the BLAST network service. In order to obtain the full mRNA sequence, 5' and 3' RACE (Rapid
- 15 Amplification of cDNA Ends) was performed using the Marathon cDNA amplification kit (Clontech). The RACE PCR product was cloned into the pCR-TRAP cloning system (GenHunter Corporation). Finally, the genes were sequenced in the forward direction to confirm the sequence. Cloning of the RACE product was unsuccessful for B60, and so for this gene probing a cDNA library is necessary.

EXAMPLE 3

EXPRESSION ANALYSIS

- 5 Liver and muscle RNA was extracted using RNazol B (Tel-Test) and adipose tissue RNA using the Rneasy RNA extraction kit (Qiagen). The RNA was reverse transcribed with AMV (Promega) to form cDNA. The level of gene expression in each cDNA sample was quantitated using Taqman PCR technology on an ABI Prism 7700 sequence detector. β -actin was used as an endogenous control to standardise the amount of cDNA
- 10 added to a reaction. Primer sequences were as follows:
- B38 forward, 5'-GGGAGAGCTGTGGAGTCAACA-3' [~~<400>~~SEQ ID NO:10];
B38 reverse, 5'-CGTGGCGACTTAGTGTAGCATT-3' [~~<400>~~SEQ ID NO:11];
B55 forward, 5'-GATGCGTTCAATGATGTCTTCCT-3' [~~<400>~~SEQ ID NO:12];
B55 reverse, 5'-AGAAGCAAACCCCATCAACTGT-3' [~~<400>~~SEQ ID NO:13];
- 15 B60 forward, 5'-TGGAGGTTCTTCGATGCTCAT-3' [~~<400>~~SEQ ID NO:14];
B60 reverse, 5'-CAGTGAAACACGTCTGCTTCTG-3' [~~<400>~~SEQ ID NO:15];
 β -actin forward, 5'-GCAAAGACCTGTATGCCAACAC-3' [~~<400>~~SEQ ID NO:16];
 β -actin reverse, 5'-GCCAGAGCAGTGATCTCTTTCTG-3' [~~<400>~~SEQ ID NO:17];
Fluorogenic probe sequences were 5'-ACCGTGCTGCCCAGGTGTCCA-3'
- 20 [~~<400>~~SEQ ID NO:18] for B38;
5'-TGAGCCCACCAAGTGAGGATTACTGATGTG-3' [~~<400>~~SEQ ID NO:19] for B55;
5'-ATCTTCTTTGAAGTGGAGTGGAGACGCTG-3' [~~<400>~~SEQ ID NO:20] for B60
and
- 25 5'-TCCGGTCCACAATGCCTGGGTACAT-3' [~~<400>~~SEQ ID NO:21] for β -actin.

The probes had the reporter dye FAM attached to the 5' end and both probes had the quencher dye TAMRA attached to the 3' end. PCR conditions were 50°C for 2 min. 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min.

EXAMPLE 4

B38

5 *Sequence and Structure*

The full sequence of the B38 transcript is 1669 nucleotides in length and encodes a protein of 354 amino acids. The protein sequence has regions of high homology to complement factor precursors C5 and C3. An 18 amino acid hydrophobic signal peptide is found at the amino terminal, which indicates that the protein is either secreted or has a transmembrane segment. However B38 is thought to be secreted since the signal sequence is very similar to that of C5 which is also secreted. One region of high homology is shared with C3a and C5a, which have an anaphylatoxin-like domain, and both of these factors have been shown to increase hepatic glucose output. Acylation stimulating protein (ASP) is a derivative of C3a and stimulates triglyceride synthesis and glucose transport in adipocytes. C3a and C5a are cleaved from the very large proteins C3 and C5, respectively, while B38 is a much smaller transcript.

Gene Expression

In the liver of *Psammomys obesus*, B38 mRNA levels positively correlate with body weight ($p < 0.01$ with all animals together, and $p < 0.001$, group B animals). There is also a positive correlation with triglycerides ($p < 0.05$). No difference in the level of expression was seen in the liver between fed and fasted animals.

A positive correlation with triglycerides was also seen in the adipose tissue ($p < 0.02$). Again, there was no significant difference between fed and fasted groups.

A positive correlation between B38 gene expression in the muscle and blood glucose levels was found ($p < 0.01$) in lean and healthy (group A) animals. This was not seen in group B or C animals.

EXAMPLE 5

B55

5 *Sequence and Structure*

The B55 mRNA is 1155 nucleotides in length and does not match any known genes in the public database, but has homology with expressed sequence tags (ESTs) from a variety of tissues. The predicted open reading frame results in a protein of 189 amino acids in *Psammomys obesus*. Mouse, rat and human sequences were deduced from ESTs
10 (3 rat, 5 mouse and 8 human sequences were used). The mouse and rat protein were found to be 188 amino acids long and were 91% and 93% homologous to the *Psammomys obesus* sequence, respectively. The human protein was found to be 187 amino acids long and was 82% homologous to the *Psammomys obesus* sequence. There were no nucleotide or amino acid differences found between lean, obese or diabetic
15 *Psammomys obesus*. B55 is located on chromosome 15 in humans from 15q26.1 to 15qter and on chromosome 7 in mice.

B55 is predicted to have one transmembrane region at residues 37 to 53 with a C-terminal cytoplasmic tail. The tail contains a coiled coil region from amino acids 79 to
20 117. Coiled coil regions are found predominantly in some structural proteins and in a class of DNA-binding proteins in which the coiled coil region is called a leucine zipper domain. The coiled coil in B55 is only about 40 residues long, much shorter than the very long coils found in many fibrous proteins such as myosin and keratin. It also does not appear to be a leucine zipper which are characterized by a leucine every seventh
25 residue. There are 5 leucines, all of which are at *a* or *d* sites but they do not line up down one side of the helix. Coiled coils are found within many other proteins, however, and mediate a wide variety of functions.

A dileucine motif was also found in the cytoplasmic tail. Dileucine motifs have been
30 shown to be involved in trans Golgi sorting, lysosomal targeting and internalization of a number of proteins. The insulin receptor, β 2-adrenergic receptor and the glucose transporter GLUT4 all have a dileucine motif which is involved in internalization.

B55 has one potential PEST sequence (RPQEEDGPGPSTSSSVTR <400>SEQ ID NO:22). Proteins with intracellular half-lives of less than two hours are found to contain regions rich in proline, glutamic acid, serine and threonine (P, E, S and T). These so called PEST regions are generally flanked by clusters of positively charged amino acids.

5

Gene Expression

B55 gene expression was found to be significantly upregulated in the liver of fasted compared to fed animals ($p < 0.0001$). This was evident in groups A, B and C, and the difference appeared more pronounced in obese, diabetic animals. A similar trend was
10 observed in the adipose tissue, with higher levels of expression after fasting ($p < 0.05$). This was found in groups B and C only, with the greatest difference in C animals.

In the fed state, there was a significant correlation between liver gene expression and blood triglyceride levels ($p < 0.01$).

15

Cell culture studies

Glucose and insulin effects - HepG2 cells (grown in high glucose media) were treated with different concentrations of insulin (5nM, 50nM and 500nM) for 4 or 24 hours. 4 hours of insulin treatment in high glucose media caused a dose-dependent decrease in
20 B55 expression. Treatment with 5nM insulin caused a 25 % reduction in B55 expression whilst 50nM and 500nM insulin caused a 42 %-43 % reduction in expression. The decrease in B55 expression with insulin treatment was statistically significant at 50nM and 500nM (ANOVA, $p < 0.05$) when compared to the untreated controls. A similar result was observed after 24 hours treatment with insulin (5nM, 50nM, 500nM) in high
25 glucose media. 5nM insulin for 24 hours caused a 23 % reduction in B55 gene expression whilst 50nM and 500nM insulin produced a 62 %-63 % reduction in expression.

EXAMPLE 6

B60

Sequence and Structure

- 5 A portion of the B60 sequence has been obtained. Only the 5' end remains to be elucidated. The mRNA transcript sequence so far is 279 nucleotides long with the most likely reading frame giving a 28 amino acid protein. This protein appears to have a transmembrane segment and is possibly located in the endoplasmic reticulum.

10 *Gene Expression*

In the liver, *B60* was seen to positively correlate with body weight ($p < 0.01$ with all animals, $p < 0.05$ A animals, $p < 0.02$ B animals). In the fasted state, *B60* expression in the muscle significantly correlates with body weight ($p < 0.05$) and with insulin ($p < 0.001$).

EXAMPLE 7

Human B55

The human ESTs used to determine the B55 cDNA sequence were (GenBank accession numbers in bold):

- 5
1. **AA305753**, Homo sapiens cDNA, Jurkat Tcells VI, Est 176916, 5' end
 2. **N42213**, Homo sapiens cDNA clone 257698, yw71e06.rl, 5' end
 3. **AA885020**, am41c08.sl Soares NFL T GBC S1 Homo sapiens cDNA clone
IMAGE:1471310, 3' end.
 - 10 4. **AA629979**, ae64fo5.s1 Stratagene lung carcinoma 937218, Homo sapiens cDNA
clone 951681, 3' end.
 5. **AA330253**, EST 33955, Embryo 12 wk II Homo sapiens cDNA, 5' end.
 6. **AA364761**, EST 75676, Pineal gland II, Homo sapiens cDNA, 5' end.
 7. **N43740**, YY 18603.R1 Soares melanocyte 2NbHM Homo Sapiens cDNA clone
15 Image: 271565 5'.
 8. **H14102**, ym62a01.rl Soares adult brain N2b4HB55Y Homo sapiens cDNA clone
IMAGE:163464 5'.

The human genomic clone containing B55 was identified by a homology search of the
20 B55 cDNA sequence against new additions to the NCBI GenBank database. The
exon/intron structure was determined by first aligning the cDNA sequence to the
genomic sequence and then applying the GT-AG rule to determine the exact boundaries.
Introns almost invariably begin with GT and end in AG.

25 The protein sequence was first deduced from the human cDNA sequence using the
ExPASy Translate program, and then confirmed using this program with the genomic
sequence once that became available.

Those skilled in the art will appreciate that the invention described herein is susceptible
30 to variations and modifications other than those specifically described. It is to be
understood that the invention includes all such variations and modifications. The
invention also includes all of the steps, features, compositions and compounds referred to
or indicated in this specification, individually or collectively, and any and all
combinations of any two or more of said steps or features.

BIBLIOGRAPHY:

- 5 Barnett M, Collier GR, Collier FM, Zimmet P, O'Dea K (1994a) A cross-sectional and short-term longitudinal characterisation of NIDDM in *Psammomys obesus*. *Diabetologia* 37: 671-676.
- Barnett M, Collier GR, Zimmet P, O'Dea K (1994b) The effect of restricting energy intake on diabetes in *Psammomys obesus*. *Int J Obesity* 18: 789-794.
- 10 Bennett SA, Magnus P (1994) Trends in cardiovascular risk factors in Australia: Results from the National Heart Foundation's Risk Factor Prevalence Study, 1980-1989. *Med J Aust* 161: 519-527.
- Bonner *et al.* (1973) *J.Mol.Biol*, 81:123.
- 15 Bouchard C. The genetics of obesity. Boca Raton: CRC Press, 1994.
- Collier GR, de Silva A, Sanigorski A, Walder K, Yamamoto A, Zimmet P (1997a) Development of obesity and insulin resistance in the Israeli Sand Rat (*Psammomys obesus*): Does leptin play a role. *Ann New York Acad Sci* 827: 50-63.
- 20 Collier GR, Walder K, de Silva A, Morton G, Zimmet P (1997b) Diabetes, obesity and leptin in the Israeli Sand Rat (*Psammomys obesus*). *Exp Clin Endocrinol Diabetes* 105: 36-37.
- 25 DeFronzo RA (1988) The triumvirate B-cell, muscle and liver: A collusion responsible for NIDDM. *Diabetes* 37: 667-688.
- Flegal, K.M., Carroll, M.D., Kuczmarski, R.J. and Johnson, C.L. (1998) *Int J Obesity* 30 22:39-47.
- Harris, M.I. (1998) *Diabetes Care* 21 (Suppl. 3):C-11-C14.
- Jonsson, B. (1998) *Diabetes Care* 21 (Suppl. 3):C7-C10.

- Kalderon B., Gutman, A., Levy, A., Shafrir, E. and Adler, J.H. (1986) *Diabetes* 6:717-724.
- 5 Martikainen, P.T. and Marmot, M.G. (1999) *Am J Clin Nutr* 69:719-726.
- Shafrir E, Gutman A (1993) *Psammomys obesus* of the Jerusalem colony: A model for nutritionally induced, non-insulin-dependent diabetes. *J Basic Clin Physiol Pharm* 4: 83-99.
- 10 Story, M., Evans, M., Fabsitz, R.R., Clay, T.E., Holy Rock, B. and Broussard, B. (1999) *Am J Clin Nutr* 69:747S-754S.
- Walder K, Dascaluc CR, Lewandowski PA, Sanigorski AJ, Zimmet P, Collier GR
15 (1997a) The effect of dietary energy restriction on the development of obesity and non-insulin-dependent diabetes mellitus (NIDDM) in *Psammomys obesus*. *Obesity Res* 5: 193-200.
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional
20 cloning of the mouse *obese* gene and its human homologue. *Nature* 372: 425-432.